Back to search
X-linked Hypophosphatemic Rickets/Osteomalacia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which X-linked Hypophosphatemic Rickets/Osteomalacia trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which X-linked Hypophosphatemic Rickets/Osteomalacia trials you may qualify forThrough observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 10 years, the study intends to collect data that allow achie…
Individual patient expanded access requests may be considered for patients who have no other treatment options
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with XLH
The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume…
Before switching to the post-marketing study: Assess the efficacy and safety of KRN23 administered subcutaneously once every 4 or 2 weeks in adult or children…
Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 administered subcutaneously once every 2 weeks in children with X-li…
The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophos…